Drugs / Peretinoin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01640808 | Apr 2012 → Oct 2016 | liver cancer | Kowa Company, Ltd. | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peretinoin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01640808 ↗ |
| Known as | NIK-333 | “NIK-333(peretinoin)” NCT01640808 ↗ |
| Modality | Small molecule | “acyclic retinoid (ACR), an orally administered vitamin A derivative” PMID 38380807 ↗ Feb 2024 |
| Route | Oral | “600mg (8 x 75mg capsules) orally, twice a day” NCT01640808 ↗ |
| Target | MYCN | “The proto-oncogene MYCN expression marked a cancer stem-like cell population in hepatocellular carcinoma (HCC) and served as a therapeutic target of acyclic retinoid (ACR)” PMID 38380807 ↗ Feb 2024 |